• Amarin Corp., of Dublin, Ireland, executed an agreement for the private placement of convertible bridge loan notes in the amount of $3 million with select accredited and institutional investors, including funds managed by Midsummer Capital LLC and certain existing investors. That money is intended to provide the firm with sufficient cash to get through Sept. 30, during which time it will continue ongoing discussions with potential investors to secure long-term equity financing. Amarin recently signed a nonbinding term sheet for a private placement of American depositary shares for up to $55 million.

• Human Genome Sciences Inc., of Rockville, Md., closed its public offering of 26.7 million shares priced at $14, including 3.5 million shares sold to cover overallotments, for total net proceeds of about $356.7 million. (See BioWorld Today, July 30, 2009.)